THOMAS BARNARD of Seeking Alpha posted today on hi
Post# of 148278
(Total Views: 1366)
Posted On: 07/22/2020 8:56:58 PM
THOMAS BARNARD of Seeking Alpha posted today on his last article:
I was pleased to hear Cytodyn plans to go with their Covid testing to the FDA for emergency approval for an unmet medical need. That's exactly the situation we are experiencing.
I was pleased to hear the cancer testing continues and that they plan to go for breakthrough designation. In figuring out how to block the CCR5 receptor to solve the HIV problem, CYDY has stumbled onto a central pathway to illness - with many targets for its CCR5 blocker (see below for a list), not the least is perhaps many different cancers. It may be an important tool in the oncologist's toolkit, perhaps by itself, or perhaps to be used with other tools. As Nader Pourhassan said the other night on DrBeen's program, it appears not to combine with other agents in any kind of lethal cocktail. It is harmless.
So, the one molecule may create a Big Pharma company, possibly the biggest. That's how it is looking to me. The testing will tell the story.
Investors need to stay the course, and not be thrown off the track by malign short sellers. Personally, I have never seen a short attack with such military precision as the one led by Andrew Left and Citron. His report may have been just a criticism. The tipoff was that he removed the report right after the attack.
If you sold shares with his attack, you need to have the courage to buy them back and hold fast. Nothing in the testing has yet indicated any reason to sell.
It is unfortunate that the SEC cannot prosecute the likes of Andrew Left because, so far, BARDA and the government and private charities have not discovered the work of Cytodyn, and it would be in the national interest to protect the capital markets from such forces because, as we have heard today, biotech development companies need the capital markets to fund their research. And for those of us who are impacted by SARS-CoV-2, which is all of us, it feels what they did was treasonous. That is, against the national interest.
I was pleased to hear Cytodyn plans to go with their Covid testing to the FDA for emergency approval for an unmet medical need. That's exactly the situation we are experiencing.
I was pleased to hear the cancer testing continues and that they plan to go for breakthrough designation. In figuring out how to block the CCR5 receptor to solve the HIV problem, CYDY has stumbled onto a central pathway to illness - with many targets for its CCR5 blocker (see below for a list), not the least is perhaps many different cancers. It may be an important tool in the oncologist's toolkit, perhaps by itself, or perhaps to be used with other tools. As Nader Pourhassan said the other night on DrBeen's program, it appears not to combine with other agents in any kind of lethal cocktail. It is harmless.
So, the one molecule may create a Big Pharma company, possibly the biggest. That's how it is looking to me. The testing will tell the story.
Investors need to stay the course, and not be thrown off the track by malign short sellers. Personally, I have never seen a short attack with such military precision as the one led by Andrew Left and Citron. His report may have been just a criticism. The tipoff was that he removed the report right after the attack.
If you sold shares with his attack, you need to have the courage to buy them back and hold fast. Nothing in the testing has yet indicated any reason to sell.
It is unfortunate that the SEC cannot prosecute the likes of Andrew Left because, so far, BARDA and the government and private charities have not discovered the work of Cytodyn, and it would be in the national interest to protect the capital markets from such forces because, as we have heard today, biotech development companies need the capital markets to fund their research. And for those of us who are impacted by SARS-CoV-2, which is all of us, it feels what they did was treasonous. That is, against the national interest.
(28)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼